Loading...
Under maintenance — back shortly
Vascular protection→white matter preservation→neurodegeneration prevention
Atorvastatin may prevent cerebrovascular decline in older adults through vascular protection, reduced white matter lesion burden, and anti-neuroinflammatory effects; the STAREE-Mind Imaging Study is a randomized placebo-controlled trial specifically testing this hypothesis in the elderly, providing high-quality evidence. This is a distinct clinical endpoint from stroke.
“STAREE-Mind Imaging Study: a randomised placebo-controlled trial of atorvastatin for prevention of cerebrovascular decline and neurodegeneration in older individuals.”
— STAREE-Mind Imaging Study: a randomised placebo-controlled trial of atorvastatin for prevention of cerebrovascular decline and neurodegeneration in older individuals. (2023)DOI“Our data demonstrate that neuroprotective effects of atorvastatin may require central nervous system delivery by Oatp-mediated transport at the blood-brain barrier, a mechanism that persists despite increased cerebrovascular permeability in ischemic stroke.”
— Oatp (Organic Anion Transporting Polypeptide)-Mediated Transport: A Mechanism for Atorvastatin Neuroprotection in Stroke. (2023)DOI